Blood:老年人确诊癌症前5个月,动脉血栓栓塞风险增高

2019-01-11 MedSci MedSci原创

中心点:在748662位参与医疗保险的人群中,确诊癌症前一年动脉血栓栓塞事件的风险增加69%。动脉血栓栓塞事件的风险于正式诊断癌症前5个月开始增高,并在前一个月达到高峰。摘要:癌症患者动脉血栓栓塞事件的风险升高;但目前还不明确风险是从什么时候开始增加。Babak B. Navi等人对确诊癌症前的动脉血栓栓塞事件风险进行评估。研究人员从数据库中筛选出374331位年满67岁的于2005-2013年间

中心点:

在748662位参与医疗保险的人群中,确诊癌症前一年动脉血栓栓塞事件的风险增加69%。

动脉血栓栓塞事件的风险于正式诊断癌症前5个月开始增高,并在前一个月达到高峰。

摘要:

癌症患者动脉血栓栓塞事件的风险升高;但目前还不明确风险是从什么时候开始增加。Babak B. Navi等人对确诊癌症前的动脉血栓栓塞事件风险进行评估。

研究人员从数据库中筛选出374331位年满67岁的于2005-2013年间确诊的癌症患者(乳腺癌、前列腺癌、结肠癌、膀胱癌、子宫癌、胰腺癌、癌和非霍奇金淋巴瘤)。并选取非癌症患者为对照,与癌症患者一对一匹配。动脉血栓栓塞事件定义为心肌梗死以及缺血性卒中。对比癌症组和非癌症组在确诊癌症前360天内的30天动脉血栓栓塞事件风险。

在癌症确诊前的360-151天,两组的30天动脉血栓栓塞事件风险相近。从癌症确诊前150-1天,癌症患者的30天动脉血栓栓塞事件风险要高于匹配的对照,而且随着癌症确诊时间的临近,风险逐渐增高,并于癌症确诊前1个月达到高峰;在癌症确诊前1个月内,2313位(0.62%)癌症患者诊断出动脉血栓栓塞,而对照组仅413位(0.11%;优势比 5.63;95% CI 5.07-6.25)。

综上所述,老年人确诊癌症前150天,动脉血栓栓塞事件的风险开始增加,并于前30天达到峰值。


原始出处:

Babak B. Navi, et al. Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood 2018 :blood-2018-06-860874; doi: https://doi.org/10.1182/blood-2018-06-860874 

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1708999, encodeId=efc11e0899999, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Sun Mar 10 04:20:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536820, encodeId=a46a153682037, content=<a href='/topic/show?id=fcbd3332949' target=_blank style='color:#2F92EE;'>#动脉血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33329, encryptionId=fcbd3332949, topicName=动脉血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=715e12724163, createdName=yangcx0919, createdTime=Sat Jan 12 15:20:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561618, encodeId=f8a31561618e7, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Jan 12 15:20:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567627, encodeId=f0a7156e627ae, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Jan 12 15:20:00 CST 2019, time=2019-01-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1708999, encodeId=efc11e0899999, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Sun Mar 10 04:20:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536820, encodeId=a46a153682037, content=<a href='/topic/show?id=fcbd3332949' target=_blank style='color:#2F92EE;'>#动脉血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33329, encryptionId=fcbd3332949, topicName=动脉血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=715e12724163, createdName=yangcx0919, createdTime=Sat Jan 12 15:20:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561618, encodeId=f8a31561618e7, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Jan 12 15:20:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567627, encodeId=f0a7156e627ae, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Jan 12 15:20:00 CST 2019, time=2019-01-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1708999, encodeId=efc11e0899999, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Sun Mar 10 04:20:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536820, encodeId=a46a153682037, content=<a href='/topic/show?id=fcbd3332949' target=_blank style='color:#2F92EE;'>#动脉血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33329, encryptionId=fcbd3332949, topicName=动脉血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=715e12724163, createdName=yangcx0919, createdTime=Sat Jan 12 15:20:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561618, encodeId=f8a31561618e7, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Jan 12 15:20:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567627, encodeId=f0a7156e627ae, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Jan 12 15:20:00 CST 2019, time=2019-01-12, status=1, ipAttribution=)]
    2019-01-12 liuxiaona
  4. [GetPortalCommentsPageByObjectIdResponse(id=1708999, encodeId=efc11e0899999, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Sun Mar 10 04:20:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536820, encodeId=a46a153682037, content=<a href='/topic/show?id=fcbd3332949' target=_blank style='color:#2F92EE;'>#动脉血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33329, encryptionId=fcbd3332949, topicName=动脉血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=715e12724163, createdName=yangcx0919, createdTime=Sat Jan 12 15:20:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561618, encodeId=f8a31561618e7, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Jan 12 15:20:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567627, encodeId=f0a7156e627ae, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Jan 12 15:20:00 CST 2019, time=2019-01-12, status=1, ipAttribution=)]
    2019-01-12 liuxiaona

相关资讯

JAMA Intern Med:癌症临床试验:无进展生存期更长表明患者生活质量更佳?

无进展生存期(PFS)现已成为常用来评估肿瘤新药有效性的结局。然而,进展的延迟是否会造成生活质量的改善,同时具有或不具有总生存期获益是未知的。2018年12月,加拿大、波兰、日本等国学者发表在《JAMA Intern Med》的一项系统评价和Meta分析,考察了PFS的评估作为肿瘤患者健康相关生活质量(HRQoL)的替代结局的效果。

急重症科:ICU的癌症患者

很多年前就认为癌症患者即便发生严重的能够逆转的急性疾病从而入住ICU也并不能获益。然而,很多研究证实这种观点并不正确。如今,全世界范围内ICU的癌症患者在逐年增加,并且同种情况下的生存率和生活质量也不断提高。这种进步的原因有很多,抗肿瘤治疗的进步有助于更好的管理ICU的患者。

Ann Oncol:癌症患者,纳武单抗每4周480 mg给药方案靠谱吗?

每4周(Q4W)480?mg的纳武单抗单药单一剂量给药方案,已获包括美国、加拿大和欧盟在内的许多市场的批准,作为多种适应症的替代给药方案。该Q4W方案的批准基于群体药代动力学(PK)分析,建立的平坦暴露-反应关系和临床安全性。2018年11月,发表在《Ann Oncol.》的一项研究调查了癌症患者纳武单抗暴露与480?mg Q4W单一剂量方案的临床安全性。

荐读|徐瑞华:为征服癌症一路奔跑

回想当年,大家立志选择医学作为终生事业,每个人都清楚这将会是一个充满艰辛、挑战和未知的旅程。今天,我们都未后悔当初的选择,我们都回归了初心。正如习近平总书记所言,‘我们永远地前行’!正是这份坚守、这份不懈努力的敬业精神、以及精益求精的医术追求,创造出一个又一个的生命奇迹。”中山大学肿瘤防治中心主任、院长徐瑞华如是说。

JACC:严重主动脉瓣狭窄的肿瘤患者进行的经导管主动脉瓣置换术

与无癌症患者相比,癌症患者的TAVR与相似的短期预后和较差的长期预后相关。

从炎症到癌症,转瞬就能发生!医生告诉您:这7种炎症格外凶险!

鼻炎、胃炎、肠炎…… 许多人会被一些炎症所困扰。 炎症这种看似不严重的“小毛病” 如果不能得到及时治疗 对身体健康会有很大的影响 甚至会演变成我们谈之色变的癌症。 炎症,有时是癌症的帮凶